Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × lenvatinib × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Recurrence 2 Osteosarcoma 2 Sarcoma, Kaposi 1 Rhabdomyosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Glioma 1 GIST 1 Central Nervous System Neoplasms 1

Interventions

Doxorubicin 20 Trabectedin 10 Radiotherapy 10 Ifosfamide 10 pazopanib 5 Gemcitabine 5 ribociclib 4 Specimen Handling 4 Docetaxel 4 Biopsy 4 selinexor 3 pembrolizumab 3 palbociclib 3 eribulin 3 X-Rays 3 Filgrastim 3 Cyclophosphamide 3 temsirolimus 2 pegfilgrastim 2 liposomal doxorubicin 2 cixutumumab 2 brostallicin 2 brigimadlin 2 belinostat 2 avelumab 2 abemaciclib 2 Vincristine 2 Temozolomide 2 Surgical Procedures, Operative 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡